

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	UCKUN ET AL.	Examiner:	UNKNOWN
Serial No.:	10/715,773	Group Art Unit:	UNKNOWN
Filed:	NOVEMBER 17, 2003	Docket:	12152.76USC2
Title:	THERAPEUTIC COMPOUNDS		

CERTIFICATE UNDER 37 CFR 1.8:

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on February 25, 2004.

By: Anna M. Nelson
Name: Anna M. Nelson

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450



Sir:

We are transmitting herewith the attached:

- ☒ Transmittal Sheet in duplicate containing Certificate of Mailing
- ☒ Information Disclosure Statement, Form 1449, 65 Reference(s)
- ☒ Return postcard

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers or any future reply, if appropriate. Please charge any additional fees or credit overpayment to Deposit Account No. 13-2725. A duplicate of this sheet is enclosed.

MERCHANT & GOULD P.C.
P.O. Box 2903, Minneapolis, MN 55402-0903
612.332.5300

By: Anna M. Nelson
Name: Anna M. Nelson
Reg. No.: 48,935
ANelson:PLStdM



10/715,773

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	UCKUN ET AL.	Examiner:	UNKNOWN
Serial No.:	10/715,773	Group Art Unit:	UNKNOWN
Filed:	NOVEMBER 17, 2003	Docket No.:	12152.76USC2
Title:	THERAPEUTIC COMPOUNDS		

CERTIFICATE UNDER 37 CFR 1.8:
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on February 25, 2004.

By: *Aeresa Morgan*
Name: Aeresa Morgan

INFORMATION DISCLOSURE STATEMENT (37 C.F.R. § 1.97(b))

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted before the mailing date of a first Office Action on-the-merits. Accordingly, no fee is due for consideration of the items listed on the enclosed Form 1449.

In accordance with 37 C.F.R. § 1.98(a)(2) and § 1.98(d), copies have been provided only for those items listed on the enclosed Form 1449 that have not previously been cited by or submitted to the U.S. Patent and Trademark Office in parent application, U.S. Serial No. 09/688,756 filed on October 16, 2000. In accordance with 37 C.F.R. § 1.98(a)(2), a copy of U.S. Patent Nos. 6,313,129 B1, 6,469,013 B2, and 6,495,556 B2 listed on the enclosed Form 1449 are not provided, as this application was filed after June 30, 2003.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a

reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.


Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.


Respectfully submitted,

MERCHANT & GOULD P.C.
P. O. Box 2903
Minneapolis, Minnesota 55402-0903
612.332.5300

Date February 25, 2004


Anna M. Nelson
Reg. No. 48,935
AMN:PLStdM



FORM 1449* 	INFORMATION DISCLOSURE STATEMENT	
	IN AN APPLICATION	
	(Use several sheets if necessary)	
Docket Number: 12152.76USC2	Application Number: 10/715,773	
Applicant: UCKUN ET AL.		
Filing Date: 11/17/2003	Group Art Unit: UNKNOWN	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	4,322,420	03/30/1982	Kobayashi et al.			
	4,343,940	08/10/1982	Kreighbaum et al.			
	4,464,375	08/07/1984	Kobayashi et al.			
	5,710,158	01/20/1998	Myers et al.			
	5,712,395	01/00/1998	App et al.			
	5,770,599	06/23/1998	Gibson			
	5,770,603	06/23/1998	Gibson			
	5,792,771	08/11/1998	App et al.			
	5,798,374	08/25/1998	Tang et al.			
	6,080,747	06/27/2000	Uckun et al.			
	6,313,129 B1	11/06/2001	Uckun et al.			
	6,469,013 B2	10/22/2002	Uckun et al.			
	6,495,556 B2	12/17/2002	Uckun et al.			

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	95/03701	02/09/1995	PCT				
	95/15758	06/15/1995	PCT				
	96/09294	03/28/1996	PCT				
	96/18639	06/20/1996	PCT				
	96/40648	12/19/1996	PCT				
	97/03069	01/1997	PCT				
	97/03358	01/30/1997	PCT				
	97/30035	08/00/1997	PCT				
	97/32856	09/1997	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Aizawa, S. et al., "An MHC-compatible allogeneic bone marrow donor with a distinct role of T cell subsets in graft-versus-leukemia effect and lethal graft-versus-host disease", <i>Bone Marrow Transplantation</i> , Vol. 16, No. 4, pp. 603-609 (October 1995).
--	---

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

FORM 1449 INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 12152.76USC2	Application Number: 10/715,773
	Applicant: UCKUN ET AL.	
	Filing Date: 11/17/2003	Group Art Unit: UNKNOWN

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
		Apperly, J. et al., "Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse", <i>Bone Marrow Transplantation</i> , Vol. 1, pp. 53-66 (1986).
		Atkinson, K. et al., "A prospective randomized trial of cyclosporin and methotrexate versus cyclosporin, methotrexate and prednisolone for prevention of graft-versus-host disease after HLA-identical sibling marrow transplantation for haematological malignancy", <i>Australian & New Zealand Journal of Medicine</i> , Vol. 21, No. 6, pp. 850-856 (December 1991).
		Barrett, A. et al., "Marrow Transplantation for Acute Lymphoblastic leukemia: factors affecting relapse and survival", <i>Blood</i> , Vol. 74, No. 2, pp. 862-871 (August 1, 1989).
		Berenson, R. et al., "Transplantation of CD34+ Hematopoietic Progenitor Cells", <i>Cancer Investigation</i> , Vol. 14, No. 6, pp. 589-596 (1996).
		Berg, R.J. et al., "Defective Global Genome Repair in XPC Mice is Associated with Skin Cancer Susceptibility But Not with Sensitivity to UVB Induced Erythema and Edema", <i>The Journal of Investigative Dermatology</i> , Vol. 110, No. 4, pp. 405-409 (April 1998).
		Bohm, H., "The development of a simple empirical scoring function to estimate the binding constant for a protein-ligand complex of known three-dimensional structure", <i>Journal of Computer-Aided Molecular Design</i> , Vol. 8, No. 3, pp. 243-256 (1994).
		Boonstra, A. et al., "Review: The role of cytokines in ultraviolet-B induced immunosuppression," <i>European Cytokine Network</i> , Vol. 8, Issue 2, pp. 117-123 (June, 1997) http://www.john-libbey-eurotext.fr/articles/ecn/8/2/117-23/ .
		Bowman, T. et al., "STATs in oncogenesis", <i>Oncogene</i> , Vol. 19, No. 21, pp. 2474-2488 (May 15, 2000).
		Bridges, A.J. et al., "Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4 - (3-bromoanilino) -6, 7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor", <i>Journal of Medicinal Chemistry</i> , Vol. 39, pp. 267-276 (1996).
		Bryson, J. et al., "Enhanced graft-versus-host disease in older recipient mice following allogeneic bone marrow transplantation", <i>Bone Marrow Transplantation</i> , Vol. 19, No. 7, pp. 721-728 (April 1, 1997).
		Buckley, R. et al., "Human severe combined immunodeficiency: Genetic, phenotypic, and functional diversity in one hundred eight infants", <i>Journal of Pediatrics</i> , Vol. 130, No. 3, pp. 378-387 (March 1997).
		Budesinsky, Z. et al., "A new synthesis of the quinazoline nucleus", <i>Collection Czechoslov Chem. Commun.</i> , Vol. 37, No. 8, pp. 2779-2785 (1972).
		Bushkin, I. et al., "Alterations in Insulin Receptor Kinase Activity During Differentiation of H1-60 Cells", <i>Biochemical and Biophysical Research Communications</i> , Vol. 172, No. 2, pp. 676-682 (October 30, 1990).
		Butturini, A. et al., "Allogeneic bone marrow transplantation for leukemia", <i>Current Opinion in Hematology</i> , Vol. 1, pp. 402-405 (1994).
		Cerutti, P.A. et al., "Inflammation and Oxidative Stress in Carcinogenesis", <i>Cancer Cells</i> , Vol. 3, No. 1, pp. 1-7 (January 1991).
		Cetkovic-Cvrlje, M. et al., "Retardation or Acceleration of Diabetes in NOD/Lt Mice Mediated by Intrathymic Administration of Candidate β -Cell Antigens", <i>Diabetes</i> , Vol. 46, No. 12, pp. 1975-1982 (December 1997).
		Cetkovic-Cvrlje, M. et al., "Targeting Janus kinase 3 to attenuate the severity of acute graft-versus-host disease across the major histocompatibility barrier in mice", <i>Blood</i> , Vol. 98, No. 5, pp. 1607-1613 (September 1, 2001).
		Choy, E. et al., "Mechanisms of Disease: Cytokine Pathways and Joint Inflammation in Rheumatoid Arthritis [Review Articles]," <i>The New England Journal of Medicine</i> , Vol. 344, No. 12, pp. 907-916 (March 22, 2001) https://www.biomedsearch.lib.umn.edu/ovidweb/ovidweb.cgi .

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 12152.76USC2	Application Number: 10/715,773
	Applicant: UCKUN ET AL.	
	Filing Date: 11/17/2003	Group Art Unit: UNKNOWN

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
		Clift, R. et al., "Allogeneic Marrow Transplantation in Patients With Acute Myeloid Leukemia in First Remission: A Randomized Trial of Two Irradiation Regimens", <i>Blood</i> , Vol. 76 No. 9, pp. 1867-1871 (November 1, 1990).
		Csar, X. et al., "Proteomic Analysis of Macrophage Differentiation," <i>The Journal of Biological Chemistry</i> , Vol. 276, No. 28, pp. 26211-26217 (July 13, 2001).
		D'Cruz, O.J. et al., "Spermicidal Activity of Metallocene Complexes Containing Vanadium (IV) in Humans", <i>Biology of Reproduction</i> , Vol. 58, No. 6, pp. 1515-1626 (June 1998).
		Danial, N.N. et al., "Jak-STAT Signaling Induced by the v-abl Oncogene", <i>Science</i> , Vol. 269, pp. 875-1877 (September 29, 1995).
		Damell Jr., J. et al., "Jak-STAT Pathways and Transcriptional Activation in Response to IFNs and Other Extracellular Signaling Proteins", <i>Science</i> , Vol. 264, pp. 1415-1421 (June 3, 1994).
		Datta, A. et al., "Distinct T cell populations distinguish chronic myeloid leukaemia cells from lymphocytes in the same individual: a model for separating GVHD from GVL reactions", <i>Bone Marrow Transplantation</i> , Vol. 14, No. 4, pp. 517-524 (October 1994).
		Deeg, H. et al., "Cyclosporine or Cyclosporine Plus Methylprednisolone for Prophylaxis of Graft-Versus-Host Disease: A Prospective, Randomized Trial", <i>Blood</i> , Vol. 89, No. 10, pp. 3880-3887 (May 15, 1997).
		Demoulin, J. et al., "A Single Tyrosine of the Interleukin-9 (IL-9) Receptor is Required for STAT Activation, Antiapoptotic Activity, and Growth Regulation by IL-9", <i>Molecular and Cellular Biology</i> , Vol. 16, No. 9, pp. 4710-4716 (September 1996).
		Devary, Y. et al., "The Mammalian Ultraviolet Response is Triggered by Activation of Src Tyrosine Kinases", <i>Cell</i> , Vol. 71, pp. 1081-1091 (December 24, 1992).
		Dinsmore, R. et al., "Allogeneic Bone Marrow Transplantation for Patients With Acute Lymphoblastic Leukemia", <i>Blood</i> , Vol. 62, No. 2, pp. 381-388 (August 1983).
		Faber, L. et al., "Generation of CD4+ Cytotoxic T-Lymphocyte Clones From a Patient With Severe Graft-Versus-Host Disease After Allogeneic Bone Marrow Transplantation: Implications for Graft-Versus-Leukemia Reactivity", <i>Blood</i> , Vol. 86, No. 7, pp. 2821-2828 (October 1, 1995).
		Falkenburg, J. et al., "Generation of Donor-Derived Antileukemic Cytotoxic T-Lymphocyte Responses for Treatment of Relapsed Leukemia After Allogeneic HLA-Identical Bone Marrow Transplantation", <i>Journal of Immunotherapy</i> , Vol. 14, No. 4, pp. 305-309 (1993).
		Fetter, J. et al., "Electron deficient heteroaromatic ammonioamides-XVIa - The synthesis and photochemistry of ethyl N-(2-methyl-4-methylene-6, 7-methylenedioxy-3, 4-dihydro-3-quinazolinyl)-N-phenylcarbamate", <i>Tetrahedron</i> , Vol. 34, No. 16, pp. 2557-2563 (1978).
		Fujii, H. et al., "Recording of mitochondrial transmembrane potential and volume in cultured rat osteoclasts by confocal laser scanning microscopy", <i>The Histochemical Journal</i> , Vol. 29, No. 8, pp. 571-581 (August 1997).
		Gosh, S. et al., "alpha-Cyano-Beta-hydroxy-Beta-methyl-N- (4-(trifluoromethoxy) phenyl) Propenamide: An Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase with Potent Cytotoxic Activity against Breast Cancer Cells", <i>Clinical Cancer Research</i> , Vol. 4, No. 11, pp. 2657 - 2668 (November 1998).
		Gilchrest, B.A. et al., "The human sunburn reaction: Histologic and biochemical studies", <i>Journal of the American Academy of Dermatology</i> , Vol 5., No. 4, pp. 411-422 (October 1981).
		Goodman, P.A. et al., "Role of tyrosine kinases in induction of the c-jun proto-oncogene in irradiated B-lineage lymphoid cells", <i>The Journal of Biological Chemistry</i> , Vol. 273, No. 28, pp. 17742 - 17748 (1998)
		Goodwin, J.S., "Immunologic Effects of Nonsteroidal Anti-Inflammatory Drugs", <i>The American Journal of Medicine</i> , pp. 7-15 (October 15, 1984).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 12152.76USC2	Application Number: 10/715,773
	Applicant: UCKUN ET AL.	
	Filing Date: 11/17/2003	Group Art Unit: UNKNOWN

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
		Grewe, M. et al., "Analysis of the Mechanism of Ultraviolet (UV) B Radiation-Induced Prostaglandin E2 Synthesis by Human Epidermoid Carcinoma Cells", <i>The Journal of Investigative Dermatology</i> , Vol. 101, No. 4, pp. 528-531 (October 1993).
		Grossman, W. et al., "Dysregulated Myelopoiesis in Mice Lacking Jak3", <i>Blood</i> , Vol. 94, No. 3, pp. 932-939 (August 1, 1999).
		Gupta, N. et al., "Delayed manifestation of ultraviolet reaction in the guinea-pig caused by anti-inflammatory drugs", <i>British Journal of Pharmacology</i> , Vol. 47, pp. 240 - 248 (1973).
		Gumiak, C.B. et al., "Murine JAK3 is Preferentially Expressed in Hematopoietic Tissues and Lymphocyte Precursor Cells", <i>Blood</i> , Vol. 87, No. 8, pp. 3151-3160 (April 15, 1996).
		Hall, E.J. et al., "Basis Radiobiology", <i>American Journal of Clinical Oncology</i> , Vol. 11, No. 3, pp. 220-252 (June 1988).
		Hanissian, S.H. et al., "Jak3 Is Associated with CD40 and Is Critical for CD40 Introduction of Gene Expression in B Cells", <i>Immunity</i> , Vol. 6, No. 4, pp. 379-387 (April 1997).
		Hanson, M. et al., "Quantitative Thresholds of MHC Class II I-E Expressed on Hemopoietically Derived Antigen-Presenting Cells in Transgenic NOD/Lt Mice Determine Level of Diabetes Resistance and Indicate Mechanism of Protection", <i>Journal of Immunology</i> , Vol. 157, No. 3, pp. 1279-1287 (August 1, 1996).
		Hawk, J.L. et al., "Responses of Normal Skin to Ultraviolet Radiation", In: <i>The Science of Photomedicine</i> , Chapter 8, Edited by J.D. Regan et al., Plenum Press, New York, pp. 219 - 260 (1982).
		Henslee-Downey, P., "Mismatched bone marrow transplantation", <i>Current Opinion in Oncology</i> , Vol. 7, No. 2, pp. 115-121 (1995).
		Hermanns, H. et al., "Non-redundant Signal Transduction of Interleukin-6-type Cytokines," <i>The Journal of Biological Chemistry</i> , Vol. 275, No. 52, pp. 40742-40748 (December 29, 2000).
		Hial, V. et al., "Alteration of Tumor Growth by Aspirin and Indomethacin: Studies with Two Transplantable Tumors in Mouse", <i>European Journal of Pharmacology</i> , Vol. 37, pp. 367-376 (1976).
		Higashino, T. et al., "Reactions of the anion of quinazoline reissert compound (3-benzoyl-3, 4- dihydro-4-quinazolinecarbonitrile) with electrophiles", <i>Chem. Pharm. Bull.</i> , Vol. 33, No. 3, pp. 950-961 (1985).
		Hoffman, S.M. et al., "JAK3 Maps to Human Chromosome 19p12 within a Cluster of Proto-oncogenes and Transcription Factors", <i>Genomics</i> , Vol. 43, pp. 109-111 (1997).
		Horita, M. et al., "Blockade of the Bcr-Abl Kinase Activity Induces Apoptosis of Chronic Myelogenous Leukemia Cells by Suppressing Signal Transducer and Activator of Transcription 5-dependent Expression of Bcl-x _L ", <i>Journal of Experimental Medicine</i> , Vol. 191, No. 6, pp. 977-984 (March 20, 2000).
		Horvath, C.M. et al., "The state of the STATs: recent developments in the study of signal transduction to the nucleus", <i>Current Opinion in Cell Biology</i> , Vol. 9, No. 2, pp. 233-239 (April 1997).
		Hruza, L.L. et al., "Mechanisms of UV-Induced Inflammation", <i>The Journal of Investigative Dermatology</i> , Vol. 100, No. 1, Supplement, pp. 35S-41S (January 1993).
		Hubbard, S.R. et al., "Crystal structure of the tyrosine kinase domain of the human insulin receptor", <i>Nature</i> , Vol. 372, No. 6508, pp. 746-754 (December 1994).
		Ife, R.J. et al., "Reversible inhibitors of the gastric (H ⁺ /K ⁺) -ATPase. 5. Substituted 2,4-diaminoquinazolines and thienopyrimidines", <i>Journal of Medicinal Chemistry</i> , Vol. 38, pp. 2763-2773 (1995).
		Ihle, J.N. et al., "Jaks and Stats in signaling by the cytokine receptor superfamily", <i>trends in GENETICS</i> , Vol. 11, No. 2, pp. 69-74 (February 1995).
		Ihle, J.N., "Janus kinases in cytokine signaling", <i>Philosophical Transactions: Biological Sciences</i> , Vol. 351, No. 1336, pp. 159-166 (February 29, 1996).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 12152.76USC2	Application Number: 10/715,773
	Applicant: UCKUN ET AL.	
	Filing Date: 11/17/2003	Group Art Unit: UNKNOWN

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
		Ihle, J.N., "The Janus Protein Tyrosine Kinase Family and its Role in Cytokine Signaling", <i>Advances in Immunology</i> , Vol. 60, Academic Press, Inc., San Diego, CA, pp. 1-35 (1995).
		Johnson, B. et al., "A Decrease in Graft-VS.-Host Disease Without Loss of Graft-VS.-Leukemia Reactivity After MHC-Matched Bone Marrow Transplantation by Selective Depletion of Donor NK Cells In Vivo", <i>Transplantation</i> , Vol. 54, No. 1, pp. 104-112 (July 1992).
		Johnson, B. et al., "Use of Anti-CD3ε F(ab') ₂ Fragments in Vivo to Modulate Graft-Versus-Host Disease Without Loss of Graft-Versus-Leukemia Reactivity After MHC-Matched Bone Marrow Transplantation", <i>Journal of Immunology</i> , Vol. 154, No. 10, pp. 5542-5554 (May 15, 1995).
		Jurlander, J. et al., "Characterization of Interleukin-10 Receptor Expression on B-Cell Chronic Lymphocytic Leukemia Cells", <i>Blood</i> , Vol. 89, No. 11, pp. 4146-4152 (June 1, 1997).
		Kaneko, S. et al., "Rescue by cytokines of apoptotic cell death induced by IL-2 deprivation of human antigen-specific T cell clones", <i>Clinical and Experimental Immunology</i> , Vol. 109, No. 1, pp. 185 - 193 (July 1997).
		Kang-Rotondo, C.H. et al., "Enhanced keratinocyte prostaglandin synthesis after UV injury is due to increased phospholipase activity", <i>American Journal of Physiology</i> , Vol. 264, No. 2, pp. C396-C401 (February 1993).
		Kaplan, G.C. et al., "Insulin Receptor Overexpression in a Human Pre-B Acute Lymphocytic Leukemia Cell Line with A t (1;19) Chromosome Translocation Near the INSR Locus", <i>Biochemical and Biophysical Communications</i> , Vol. 159, No. 3, pp. 1275-1282 (March 31, 1989).
		Klapan, I. et al., "Prognostic significance of plasma prostaglandin E concentration in patients with head and neck cancer", <i>Journal of Cancer Research and Clinical Oncology</i> , Vol. 118, No. 4, pp. 308-313 (1992).
		Konger, R.L. et al., "Growth regulation of primary human keratinocytes by prostaglandin E receptor EP2 and EP3 subtypes", <i>Biochimica et Biophysica Acta</i> , Vol. 1401, pp. 221-234 (1998).
		Komgold, R. et al., "Graft-Versus-Myeloid Leukemia Responses Following Syngeneic and Allogeneic Bone Marrow Transplantation", <i>Transplantation</i> , Vol. 58, No. 3, pp. 278-287 (August 15, 1994).
		Krolick, K., et al., "Murine B Cell Leukemia (BCL ₁): Organ Distribution And Kinetics of Growth as Determined by Fluorescence Analysis With An Anti-Idiotypic Antibody", <i>Journal of Immunology</i> , Vol. 123, No. 5, pp. 1928-1935 (November 1979).
		Kubo, K. et al., "A Novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of pdgf receptor autophosphorylation", <i>Bioorganic & Medicinal Chemistry Letters</i> , Vol. 7, No. 23, pp. 2935 - 2940 (1997).
		Kuby, J., "Chapter 3: Cells and Organs of the Immune System," <i>Immunology, Second Edition</i> , pp. 50-52 (1994).
		Kuby, J., "Autoimmune Diseases in Humans: Organ-Specific Autoimmune Diseases," <i>Immunology, Second Edition</i> , pp. 447 (1994).
		Kumar, A. et al., "Structural Organization and Chromosomal Mapping of JAK3 Locus", <i>Onogene</i> , Vol. 13, No. 9, pp. 2009 - 2014 (November 7, 1996).
		Lalani, I. et al., "Review Article: Interleukin-10: biology, role in inflammation and autoimmunity," <i>Annals Of Allergy, Asthma, & Immunology</i> , Vol. 79, pp. 469-484 (December, 1997).
		Leelasiri, A. et al., "Graft-versus-host-disease prophylaxis for matched unrelated donor bone marrow transplantation: comparison between cyclosporine-methotrexate and cyclosporine-methotrexate-methylprednisolone", <i>Bone Marrow Transplantation</i> , Vol. 15, No. 3, pp. 401-405 (March 1995).
		Leonard, W.J., "STATs and Cytokine Specificity", <i>Nature Medicine</i> , Vol. 2, No. 9, pp. 968-969 (September 1996).
		Levy, D.E., "The House that JAK/STAT Built", <i>Cytokine & Growth Factor Reviews</i> , Vol. 8, No. 1, pp. 81-90 (March 1997).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 12152.76USC2	Application Number: 10/715,773
	Applicant: UCKUN ET AL.	
	Filing Date: 11/17/2003	Group Art Unit: UNKNOWN

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
		Ley, R.D. et al., "Rapid Communication Ultraviolet Radiation-Induced Malignant Melanoma in Monodelphis Domestica", <i>Photochemistry and Photobiology</i> , Vol. 50, No. 1, pp. 1-5 (1989)
		Lynch, N.R. et al., "Mechanism of Inhibition of Tumour Growth by Aspirin and Indomethacin", <i>The British Journal of Cancer</i> , Vol. 38, No. 4, pp. 503-512 (October 1978).
		Maftah, A. et al., "10-N Nonyl-Acridine Orange: A Fluorescent Probe which Stains Mitochondria Independently of their Energetic State", <i>Biochemical and Biophysical Communications</i> , Vol. 164, No. 1, pp. 185-190 (October 16, 1989).
		Mahajan, S. et al., "Rational Design and synthesis of a Novel Anti-leukemic Agent Targeting Bruton's Tyrosine Kinase (BTK), LFM-A13 (alpha-Cyano-Beta-Hydroxy-Beta-Methyl-N- (2, 5-Dibromophenyl) Propenamide)", <i>The Journal of Biological Chemistry</i> , Vol. 274, No. 14, pp. 9587-9599 (April 1, 1999).
		Mahajan, S. et al., "Src Family Protein Tyrosine Kinases Induce Autoactivation of Bruton's Tyrosine Kinase", <i>Molecular and Cell Biology</i> , Vol. 15, No. 10, pp. 5304-5311 (October 1995).
		Malaviya, R. et al., "Genetic and Biochemical evidence for a critical role of Janus Kinase (JAK)-3 in mast cell-mediated type I hypersensitivity reactions", <i>Biochemistry and Biophysical Research Communications</i> , Vol. 257, No. 3, pp. 807-813 (1999).
		Mancini, M. et al., "Mitochondrial Proliferation and Paradoxical Membrane Depolarization during Terminal Differentiation and Apoptosis in a Human Colon Carcinoma Cell Line", <i>The Journal of Cell Biology</i> , Vol. 138, No. 2, pp. 449-469 (July 28, 1997).
		Marks, R., "An Overview of Skin Cancers - Incidence and Causation", <i>Supplement to Cancer</i> , Vol. 75, No. 2, pp. 607-612 (January 15, 1995).
		Marmont, A. et al., "T-Cell Depletion of HLA-Identical Transplants in Leukemia", <i>Blood</i> , Vol. 78, No. 8, pp. 2120-2130 (October 15, 1991).
		Martin, P. et al., "Graft failure in patients receiving T cell-depleted HLA-identical allogeneic marrow transplants", <i>Bone Marrow Transplantation</i> , Vol. 3, No. 5, pp. 445-456 (September 1988).
		Matherly, L. et al., "Methotrexate Pharmacology and Resistance in Childhood Acute Lymphoblastic Leukemia", <i>Leukemia & Lymphoma</i> , Vol. 21, Nos. 5/6, pp. 359-368 (1996).
		Mellet, P. et al., "Stopped Flow Fluorescence Energy Transfer Measurement of the Rate Constants Describing the Reversible Formation and the Irreversible Rearrangement of the Elastase-Alpha-Proteinase Inhibitor Complex", <i>The Journal of Biological Chemistry</i> , Vol. 273, No. 15, pp. 9119-9123 (April 10, 1998).
		Messinger, Y. et al., "In Vivo Toxicity and Pharmacokinetic Features of B43 (Anti-CD19) -Genistein Immunoconjugate in Nonhuman Primates", <i>Clinical Cancer Research</i> , Vol. 4, pp. 165-170 (January 1998).
		Mitchell, P.D. et al., "Transcriptional Regulation in Mammalian Cells by Sequence-Specific DNA Binding Proteins", <i>Science</i> , Vol. 245, pp. 371-378 (July 21, 1989).
		Miyashita, A. et al., "An approach to the synthesis of apavaverine analogue containing a quinazoline ring system", <i>Heterocycles</i> , Vol. 40, No. 2, pp. 653-660 (March 1995).
		Miyazaki, T. et al., "Coupling of the IL2 Receptor Complex with Non-receptor Protein Tyrosine Kinases", <i>Cancer Surveys</i> , Vol. 27, pp. 25-40 (1996).
		Mohammadi, M. et al., "Structure of the FGF Receptor Tyrosine Kinase Domain Reveals a Novel Autoinhibitory Mechanism", <i>Cell</i> , Vol. 86, pp. 577-587 (August 23, 1996).
		Mohammadi, M. et al., "Structures of the Tyrosine Kinase Domain of Fibroblast Growth Factor Receptor in Complex with Inhibitors", <i>Science</i> , Vol. 276, pp. 955-960 (May 9, 1997).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 12152.76USC2	Application Number: 10/715,773
	Applicant: UCKUN ET AL.	
	Filing Date: 11/17/2003	Group Art Unit: UNKNOWN

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
		Myers, D.E. et al., "Membrane-associated CD219-LYN complex is an endogenous p53-independent and Bcl-2-independent regulator of apoptosis in human B-lineage lymphoma cells", <i>Proceedings of the National Academy of Sciences</i> , Vol. 92, No. 21, pp. 9575-9579 (October 10, 1995).
		Myers, M.R. et al., "The preparation and sar of 4-(anilino), 4-(phenoxy), and 4-(thiophenoxy) -quinazolines: inhibitors of p56lck and EGF-R tyrosine kinase activity", <i>Bioorganic & Medicinal Chemistry Letters</i> , Vol. 7, No. 4, pp. 417-420 (1997).
		Nakamura, N. et al., "An epidermal Growth Factor Receptor/Jak2 Tyrosine Kinase Domain Chimera Induces Tyrosine phosphorylation of Stat5 and Transduces a Growth Signal in Hematopoietic Cells", <i>The Journal of Biological Chemistry</i> , Vol. 271, No. 32, pp. 19483-19488 (August 9, 1996).
		Narla, R.K. et al., "4-(3'-Bromo-4' hydroxyphenyl) -amino-6, 7-dimethoxyquinazoline: A novel quinazoline derivative with potent cytotoxic activity against human glioblastoma cells", <i>Clinical Cancer Research</i> , Vol. 4, No. 6, pp. 1405-1414 (June 1998).
		Newman, J.D. et al., "Enhanced Insulin-Receptor Tyrosine Kinase Activity Associated with Chromosomal Translocation (1; 19) in a Pre-B-Cell Leukemia Line", <i>International Journal of Cancer</i> , Vol. 50, No. 3, pp. 500-504 (February 1, 1992).
		Nomoto, Y. et al., "Studies on Cardiotonic Agents. I. Synthesis of Some Quinazoline Derivatives", <i>Chemical & Pharmaceutical Bulletin</i> , Vol. 38, No. 6, pp. 1591-1595 (June 1990).
		Nosaka, T. et al., "Defective Lymphoid Development in Mice Lacking Jak3", <i>Science</i> , Vol. 270, pp. 800-802 (November 3, 1995).
		Orchard, P. et al., "Graft-versus-leukemia is sufficient to induce remission in juvenile myelomonocytic leukemia", <i>Bone Marrow Transplantation</i> , Vol. 22, No. 2, pp. 201-203 (July 2, 1998).
		O'Reilly, R., "Allogeneic Bone Marrow Transplantation: Current Status and Future Directions", <i>Blood</i> , Vol. 62, No. 5, pp. 941-964 (November 1983).
		O'Reilly, R. et al., "Allogeneic Transplantation", <i>Cancer medicine</i> , Vol. 1, 4th Edition, Chapter 86, pp. 1295-1324 (1997).
		Patterson, A. et al., "Infusion of Select Leukemia-Reactive TCR Vβ ⁺ T Cells Provides Graft-Versus-Leukemia Responses With Minimization of Graft-Versus-Host Disease Following Murine Hematopoietic Stem Cell Transplantation", <i>Biology of Blood and Marrow Transplantation</i> , Vol. 7, No. 4, pp. 187-196 (2001).
		Petit, P.X. et al., "Alterations in Mitochondrial Structure and Function Are Early Events of Dexamethasone-Induced Thymocyte Apoptosis", <i>The Journal of Cell Biology</i> , Vol. 130, No. 1, pp. 157-167 (July 1995).
		Plescia, O.J. et al., "Subversion of Immune System by Tumor Cells and Role of Prostaglandins", <i>Proceedings of the National Academy of Sciences</i> , Vol. 72, No. 5, pp. 1848 - 1851 (May 1975).
		Porter, D. et al., "Long-term follow-up of patients who achieved complete remission after donor leukocyte infusions", <i>Biology of Blood and Marrow Transplantation</i> , Vol. 5, No. 4, pp. 253-261 (1999).
		Poynton, C., "T cell depletion in bone marrow transplantation", <i>Bone Marrow Transplantation</i> , Vol. 3, No. 4, pp. 265-279 (July 1988).
		Ramsay, N. et al., "Indications for Marrow Transplantation in Acute Lymphoblastic Leukemia", <i>Blood</i> , Vol. 75, No. 4, pp. 815-818 (February 15, 1990).
		Rewcastle, G.W. et al., "Tyrosine Kinase Inhibitors. 5. Synthesis and Structure-Activity Relationships for 4-(Phenylmethyl) amino) - and 4-(Phenylamino) quinazolines as Potent Adenosine 5'-Triphosphate Binding Site Inhibitors of the Tyrosine Kinase Domain of the Epidermal Growth", <i>Journal of Medicinal Chemistry</i> , Vol. 38, No. 18, pp. 3482-3487 (1995).
		Riedy, M.C. et al., "Genomic Sequence, Organization, and Chromosomal Localization of Human JAK3", <i>Genomic</i> , Vol. 37, No. 1, pp. 57-61 (October 1, 1996).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 12152.76USC2	Application Number: 10/715,773
	Applicant: UCKUN ET AL.	
	Filing Date: 11/17/2003	Group Art Unit: UNKNOWN

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
		Rolling, C. et al., "JAK3 associates with the human Interleukin 4 receptor and is tyrosine phosphorylated following receptor triggering", <i>Onogene</i> , Vol. 10, No. 9, pp. 1757 - 1761 (May 4, 1995).
		Rosette, C. et al., "Ultraviolet Light and Osmotic Stress: Activation of the JNK Cascade Through Multiple Growth Factor and Cytokine Receptors", <i>Science</i> , Vol. 274, pp. 1194 - 1197 (November 15, 1996).
		Ruutu, T. et al., "Cyclosporine, methotrexate, and methylprednisolone compared with cyclosporine and methotrexate for the prevention of graft-versus-host disease in bone marrow transplantation from HLA-identical sibling donor: a prospective randomized study", <i>Blood</i> , Vol. 96, No. 7, pp. 2391-2398 (October 1, 2000).
		Sack, J.S., "CHAIN - A Crystallographic Modeling Program", <i>Journal of Molecular Graphics</i> , Vol. 6, No. 1, pg. 224 (March 1988).
		Safford, M. et al., "JAK3: A Member of the Jak Family of Non-Receptor Tyrosine Kinases is Expressed in the stem/origenitor cell fraction of human bone marrow", <i>Blood</i> , Vol. 84, No. 10 Suppl. 1, Abstract No. 475, 122a.
		Safford, M.G. et al., "JAK3: Expression and Mapping to Chromosome 19p12 - 13.1", <i>Experimental Hematology</i> , Vol. 25, No. 5, pp. 374-386 (May 1997).
		Salam, A. et al., Graft-Versus-Host Reactivity and Graft-Versus-Leukemia Effect in Murine Allogeneic Bone Marrow Chimeras Conditioned With Total Body Irradiation or Total Lymphoid Irradiation", <i>Transplantation</i> , Vol. 61, No. 5, pp. 826-830 (March 15, 1996).
		Schmaltz, C. et al., "Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect", <i>Blood</i> , Vol. 97, No. 9, pp. 2886-2895 (May 1, 2001).
		Sharfee, N. et al., "Jak3 Activation in Human Lymphocyte precursor Cells", <i>Clinical and Experimental Immunology</i> , Vol. 108, No. 3, pp. 552-556 (June 1997).
		Sicheri, F. et al., "Crystal Structure of the Src Family Tyrosine Kinase Hck", <i>Nature</i> , Vol. 385, No. 6617, pp. 603-609 (February 13, 1997).
		Slavin, S. et al., "Spontaneous murine B-cell leukaemia", <i>Nature</i> , Vol. 272, No. 5654, pp. 624-626 (April 13, 1978).
		Slavin, S. et al., "Ultrastructural, Cell Membrane, and Cytogenetic Characteristics of B-Cell Leukemia, a Murine Model of Chronic Lymphocytic Leukemia", <i>Cancer Research</i> , Vol. 41, No. 10, pp. 4162-4166 (October 1981).
		Slavin, S. et al., "Non-myeloablative allogeneic stem cell transplantation focusing on immunotherapy of life-threatening malignant and non-malignant diseases", <i>Critical Reviews in Oncology/Hematology</i> , Vol. 39, pp. 25-29 (2001).
		Smiley, S.T. et al., "Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation JC-1", <i>Proceedings of the National Academy of Sciences</i> , Vol. 88, No. 9, pp. 3671-3675 (May 1991).
		Smith, P.K. et al., "Measurement of Protein Using Bicinchoninic Acid", <i>Analytical Biochemistry</i> , Vol. 150, pp. 76-85 (1985).
		Snyder, D.S. et al., "Intradermal Anti-Prostaglandin Agents and Sunburn", <i>The Journal of Investigative Dermatology</i> , Vol. 62, No. 1, pp. 47-50 (January 1974).
		Snyder, D.S. et al., "Topical indomethacin and sunburn", <i>British Journal of Dermatology</i> , Vol. 90, No. 1, pp. 91-93 (January 1974).
		Snyderman, C.H. et al., "Inhibition of Growth of a Murine Squamous Cell Carcinoma by a Cyclooxygenase Inhibitor Increases Leukotriene B4 Production", <i>Archives of Otolaryngology - Head & Neck Surgery</i> , Vol. 121, pp. 1017-1020 (September 1995).
		Sosman, J. et al., "Specific Recognition of Human Leukemic Cells by Allogeneic T Cells: II. Evidence for HLA-D Restricted Determinants on Leukemic Cells That Are Crossreactive With Determinants Present on Unrelated Nonleukemic Cells", <i>Blood</i> , Vol. 75, No. 10, pp. 2005-2016 (May 15, 1990).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 12152.76USC2	Application Number: 10/715,773
	Applicant: UCKUN ET AL.	
	Filing Date: 11/17/2003	Group Art Unit: UNKNOWN

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
		Spitzer, T. et al., "Intentional Induction of Mixed Chimerism and Achievement of Antitumor Responses After Nonmyeloablative Conditioning Therapy and HLA-Matched Donor Bone Marrow Transplantation for Refractory Hematologic Malignancies", <i>Biology of Blood and Marrow Transplantation</i> , Vol. 6, pp. 309-320 (2000).
		Storb, R. et al., "What Role for Prednisone in Prevention of Acute Graft-Versus-Host Disease in Patients Undergoing Marrow Transplants?", <i>Blood</i> , Vol. 76, No. 5, pp. 1037-1045 (September 1, 1990).
		Sudbeck, E.A. et al., "Structure-based Design of Specific Inhibitors of Janus Kinase 3 as Apoptosis-inducing Antileukemic Agents", <i>Clinical Cancer Research</i> , Vol. 5, pp. 1569-1582 (June 1999).
		Sykes, M. et al., "Interleukin-2 Inhibits Graft-Versus-Host Disease-Promoting Activity of CD4 ⁺ Cells While Preserving CD4- and CD8-Medicated Graft-Versus-Leukemia Effects", <i>Blood</i> , Vol. 83, No. 9, pp. 2560-2569 (May 1, 1994).
		Thomas, E. et al., "Indications for Marrow Transplantation in Chronic Myelogenous Leukemia", <i>Blood</i> , Vol. 73, No. 4, pp. 861-864 (March 1989).
		Thomas, E., "Stem Cell Transplantation: Past, Present and Future", <i>Archivum Immunologiae & Therapiae Experimentalis</i> , Vol. 45, No. 1, pp. 1-5 (1997).
		Thomis, D.C. et al., "Defects in B Lymphocyte Maturation and T Lymphocyte Activation in Mice Lacking Jak3", <i>Science</i> , Vol. 270, pp. 794-797 (November 3, 1995).
		Tortolani, P.J. et al., "Regulation of JAK3 Expression and Activation in Human B Cells and B Cell Malignancies", <i>The Journal of Immunology</i> , Vol. 155, No. 11, pp. 5220 - 5226 (December 1, 1995).
		Trigg, M., "Bone Marrow Transplantation for Treatment of Leukemia in Children", <i>Pediatric Clinics of North America</i> , Vol. 35, No. 4, pp. 933-948 (August 1988).
		Tuel-Ahlgren, L. et al., "Role of Tyrosine Phosphorylation in Radiation-Induced Cell Cycle-Arrest of Leukemia B-Cell Precursors at the G2-M Transition Checkpoint", <i>Leukemia and Lymphoma</i> , Vol. 20, No. 5-6, pp. 417-426 (1996).
		Truitt, R. et al., "Contribution of CD4 ⁺ and CD8 ⁺ T cells to graft-versus-host disease and graft-versus-leukemia reactivity after transplantation of MHC-compatible bone marrow", <i>Bone Marrow Transplantation</i> , Vol. 8, No. 1, pp. 51-58 (July 1991).
		Tsukada, N. et al., "Graft-Versus-Leukemia Effect and Graft-Versus-Host Disease Can Be Differentiated by Cytotoxic Mechanisms in a Murine Model of Allogeneic Bone Marrow Transplantation", <i>Blood</i> , Vol. 93, No. 8, pp. 2738-2747 (April 15, 1999).
		Uckun, F.M. et al., "Biotherapy of B-Cell Precursor Leukemia by Targeting Genistein to CD 19-Associated Tyrosine Kinases", <i>Science</i> , Vol. 267, pp. 886-891 (February 10, 1995).
		Uckun, F.M. et al., "Cytotoxic Activity of Epidermal Growth Factor-Genistein against Breast Cancer Cells", <i>Clinical Cancer Research</i> , Vol. 4, No. 4, pp. 901-912 (April 1998).
		Uckun, F.M. et al., "Immunobiologic differences between normal and leukemic human B-cell precursors", <i>Proceedings Natl. Acad. Sci. USA</i> , Vol. 85, No. 22, pp. 8603-8607 (November 1988).
		Uckun, F.M. et al., "In Vivo Efficacy of B43 (anti-CD19)-Pokeweed Antiviral Protein Immunotoxin Against BCL-1 Murine B-Cell Leukemia", <i>Blood</i> , Vol. 79, No. 10, pp. 2649-2661 (May 15, 1992).
		Uckun, F.M. et al., "In Vivo Toxicity and Pharmacokinetic Features of the Janus Kinase 3 Inhibitor WHI-P131 [4-(4-Hydroxyphenyl)-Amino-6,7-Dimethoxyquinazoline]", <i>Clinical Cancer Research</i> , Vol. 5, No. 10, pp. 2954-2962 (October 1999).
		Uckun, F.M. et al., "Physical and Functional Interactions between Lyn and p34cdc2 Kinases in Irradiated Human B-cell Precursors", <i>The Journal of Biological Chemistry</i> , Vol. 271, No. 11, pp. 6389-6397 (March 15, 1996).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 12152.76USC2	Application Number: 10/715,773
	Applicant: UCKUN ET AL.	
	Filing Date: 11/17/2003	Group Art Unit: UNKNOWN

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
		Uckun, F.M. et al., "Temporal Association of CD40 Antigen Expression With Discrete Stages of Human B-Cell Ontogeny and the Efficacy of Anti-CD40 Immunotoxins Against Clonogenic B-Lineage Acute Lymphoblastic Leukemia as Well as B-Lineage Non-Hodgkin's Lymphoma Cells" <i>Blood</i> , Vol. 76, No. 12, pp. 2449-2456 (December 15, 1990).
		Uckun, F.M. et al., "Use of a Novel Colony Assay to Evaluate the Cytotoxicity of an Immunotoxin Containing Pokeweed Antiviral Protein Against Blast Progenitor Cells Freshly Obtained from Patients with Common B- Lineage Acute Lymphoblastic Leukemia", <i>The Journal of Experimental Medicine</i> , Vol. 163, pp. 347-368 (February 1986).
		Van Lochem, E. et al., In vitro separation of host specific graft-versus-host and graft-versus-leukemia cytotoxic T cell activities", <i>Bone Marrow Transplantation</i> , Vol. 10, No. 2, pp.181-183 (August 1992).
		Vanderveen, E.E. et al., "Arachidonic Acid Metabolites in Cutaneous Carcinomas", <i>Archives of Dermatology</i> , Vol. 122, No. 4, pp. 407-412 (April 1986).
		Vassilev, A. et al., "Bruton's Tyrosine Kinase as an Inhibitor of the Fas/CD95 Death-inducing Signaling complex", <i>The Journal of Biological Chemistry</i> , Vol. 274, No. 3, pp. 1646-1656 (January 15, 1999).
		Verheij, M. et al., "Requirement for Ceramide-Initiated SAPK/JNK Signaling in Stress-Induced Apoptosis", <i>Nature</i> , Vol. 380, No. 6569, pp. 75-79 (March 7, 1996).
		Villa, A. et al., "Monocyte Function in a Severe Combined Immunodeficient Patient With a Donor Splice Site Mutation in the Jak3 Gene", <i>Blood</i> , Vol. 88, No. 3, pp. 817-823 (August 1, 1996).
		Vourka-Karussis, U. et al., "Enhancement of GVL effect with rhIL-2 following BMT in a Murine model for acute myeloid leukemia in SJL/J mice", <i>Experimental Hematology</i> , Vol. 23, No. 3, pp. 196-201 (March 1995).
		Waddick, K. et al., "In Vivo Radiosensitizing Effects of Recombinant Interleukin 6 on Radiation Resistant BCL-1 B-Lineage Leukemia Cells in a Murine Syngeneic Bone Marrow Transplant Model System", <i>Leukemia & Lymphoma</i> , Vol. 19, Nos. 1/2, pp. 121-128 (1995).
		Wingard, J. et al., "Allogeneic Bone Marrow Transplantation for Patients With High-Risk Acute Lymphoblastic Leukemia", <i>Journal of Clinical Oncology</i> , Vol. 8, No. 5, pp. 820-830 (May 1990).
		Witthuhn, B.A. et al., "Differential Substrate Recognition Capabilities of Janus Family Protein Tyrosine Kinases Within the Interleukin 2 Receptor (IL2R) System: Jak3 as a Potential Molecular Target for Treatment of Leukemias with a Hyperactive Jak-Stat Signaling Machinery", <i>Leukemia and Lymphoma</i> , Vol. 32, No. 3/4, pp. 289-297 (1999).
		Woodward, D.F. et al., "Re-evaluation of the effect of non-steroidal anti-inflammatory agents on u.v.-induced cutaneous inflammation", <i>Agents and Actions</i> , Vol. 11, No. 6/7, pp. 711-717 (December 1981).
		Xiao, J. et al., "Signal Transduction through the Beta1 Integrin Family Surface. Adhesion Molecules VLA-4 and VLA-5 of Human B-cell Precursors Activates CD19 Receptor-associated Protein-tyrosine Kinases", <i>The Journal of Biological Chemistry</i> , Vol. 271, No. 13, pp. 7659-7664 (March 29, 1996).
		Yeh, T. et al., "The Janus kinase family of protein tyrosine kinases and their role in signaling," <i>CMLS Cell. Mol. Life Sci.</i> , Vol. 55, pp. 1523-1534 (1999).
		Zhu, D. et al., "Calphostin C Triggers Calcium-dependent Apoptosis in Human Acute Lymphoblastic Leukemia Cells", <i>Clinical Cancer Research</i> , Vol. 4, No. 12, pp. 2967 - 2976 (December 1998).

23552

PATENT TRADEMARK OFFICE

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	